Comparative Pharmacology
Head-to-head clinical analysis: ALUNBRIG versus NINTEDANIB ESYLATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALUNBRIG versus NINTEDANIB ESYLATE.
ALUNBRIG vs NINTEDANIB ESYLATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Alunbrig (brigatinib) is a tyrosine kinase inhibitor that targets ALK and ROS1. It inhibits autophosphorylation of ALK and ALK-mediated activation of downstream signaling proteins STAT3, AKT, ERK1/2, and PLCγ in ALK-dependent tumor cells.
Nintedanib esylate is a tyrosine kinase inhibitor that binds competitively to the ATP-binding pocket of vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), platelet-derived growth factor receptors (PDGFR-α, PDGFR-β), and fibroblast growth factor receptors (FGFR-1, FGFR-2, FGFR-3). This inhibition blocks downstream signaling pathways involved in angiogenesis and fibrosis.
90 mg orally once daily for first 7 days, then increase to 180 mg orally once daily
150 mg orally twice daily, 12 hours apart, taken with food.
None Documented
None Documented
Terminal half-life approximately 25 hours. Supports once-daily dosing; steady state achieved in ~5 days.
Terminal elimination half-life is approximately 10 hours in patients with IPF; steady state reached within 7 days.
Primarily hepatic metabolism (CYP3A4); 65% fecal (unchanged and metabolites), 25% renal (1% unchanged). Biliary excretion contributes to fecal elimination.
Biliary/fecal: >90% (unchanged and metabolites); Renal: <1%
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor